Use of lipid-, blood pressure–, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease

AJ Nelson, EC O'Brien, LA Kaltenbach… - JAMA Network …, 2022 - jamanetwork.com
Importance Based on contemporary estimates in the US, evidence-based therapies for
cardiovascular risk reduction are generally underused among patients with type 2 diabetes …
被引用次数：37 相关文章

Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

AJ Nelson, EC O'Brien… - JAMA …, 2022 - utsouthwestern.elsevierpure.com
Importance: Based on contemporary estimates in the US, evidence-based therapies for
cardiovascular risk reduction are generally underused among patients with type 2 diabetes …

Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

AJ Nelson, EC O'Brien, LA Kaltenbach… - JAMA network …, 2022 - pubmed.ncbi.nlm.nih.gov
Importance Based on contemporary estimates in the US, evidence-based therapies for
cardiovascular risk reduction are generally underused among patients with type 2 diabetes …

Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.

AJ Nelson, EC O'Brien, LA Kaltenbach… - JAMA Network …, 2022 - europepmc.org
Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type
2 Diabetes and Atherosclerotic Cardiovascular Disease. - Abstract - Europe PMC Sign in …
[HTML] nih.gov

[HTML][HTML] Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

AJ Nelson, EC O'Brien, LA Kaltenbach… - JAMA Network …, 2022 - ncbi.nlm.nih.gov
Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With
Type 2 Diabetes and Atherosclerotic Cardiovascular Disease - PMC Back to Top Skip to …

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.

AJ Nelson, EC O'Brien, LA Kaltenbach… - JAMA Network …, 2022 - search.ebscohost.com
Abstract Key Points: Question: What is the contemporary pattern of evidence-based
pharmacotherapy use among a real-world population of US patients with type 2 diabetes …

Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.

AJ Nelson, EC O'Brien, LA Kaltenbach… - JAMA Network …, 2022 - europepmc.org
Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type
2 Diabetes and Atherosclerotic Cardiovascular Disease. - Abstract - Europe PMC Sign in …